Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Luce Wildebeest who wrote (897)	5/1/2000 1:37:00 PM
From: david james	Respond to of 1298

Basically, JT gets the Asian rights to the cancer vaccine by paying for half of the development costs of the vaccine cellgenesys.com The company is developing GVAX© cancer vaccines for prostate cancer and lung cancer through a worldwide collaboration with the pharmaceutical division of Japan Tobacco (JT). Under this collaboration, the two companies will share equally in product development costs and future profits. Cell Genesys will have marketing rights in North America, JT will have marketing rights in Japan, Taiwan and Korea, and the companies will share rights in Europe and the rest of the world. Cell Genesys expects to receive approximately $45 million during the first two years of this collaboration.

To: Luce Wildebeest who wrote (897)	5/1/2000 3:25:00 PM
From: david james	Respond to of 1298

Here are some previous stories about the vaccine although they don't always mention Cell Genesys (the last one does though). More results should be presented at ASCO around May 23. wired.com pslgroup.com msnbc.com onhealth.com quad-net.com

To: Luce Wildebeest who wrote (897)	5/5/2000 3:51:00 PM
From: david james	Read Replies (1) \| Respond to of 1298

ABGX moving up (probably on Genentech's news) and CEGE getting dragged along with it. Each $6 move of ABGX increases CEGE's book value by $1. Currently ABGX is at $113 4.852 mill shares x 113 = $548 million $250 mill in cash $15 mill in facilities etc Book value is around $813 mill with 36 mill shares = $22.60 Genentech's very successful MAB drug Herceptin was found to produce a fatal allergic reaction in a small number of cases. This would not occur with a fully human MAB like that produced by ABGX. This demonstrates the importance of the ABGX and MEDX technology. _______________________________________________________ Currently there are about eight antibody products on the market, including Genentech Inc.'s Herceptin for breast cancer. But those products are part mouse and part human, so-called hybrid antibodies. Abgenix and Medarex would distinguish themselves by being ``fully human.'' ... Scientists have been trying to harness the potential therapeutic power of antibodies since the early 1980s, with little success until the newer hybrid antibodies came along in the last two years. Typically, drug makers create hybrid antibodies out of genetically engineered combinations of human and mouse gene fragments. But because these antibodies contain small bits of mouse protein, they trigger an immune response, which can include potentially fatal fever. from biocognizance.com

To: Luce Wildebeest who wrote (897)	5/8/2000 11:30:00 AM
From: david james	Read Replies (1) \| Respond to of 1298

Conferences CEGE will be presenting some of the results of their trials with their prostate cancer vaccine next week. IMPORTANT ADVANCES IN CANCER RESEARCH TO BE PRESENTED AT THE ASCO 2000 ANNUAL MEETING More than 20,000 cancer professionals from around the world will gather at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO) at the Ernest N. Morial Convention Center in New Orleans from May 20-23, 2000. Beginning Saturday, May 20th, ASCO will hold seven media briefings featuring significant research being presented at the Annual Meeting, and reviewing important areas of concern in the field of cancer care. All research is embargoed until the date and time of scientific presentation. asco.org Two weeks later is an investors conference marketwatch.newsalert.com On Saturday June 3, Informed Investors will host its Fifth Beltway Biotechnology Stocks Forum highlighting genomics. The keynote speaker is analyst Akhtar Samad, M.D., Ph.D., of Oscar Gruss & Co. Companies slated to present are Cell Genesys, CuraGen, Gene Logic, Genome Therapeutics, Genzyme Molecular Oncology, Human Genome Sciences, ISIS Pharmacueticals, Lynx Therapeutics, Sequenom, Targeted Genetics, Trega Biosciences, Vical and Vysis, Inc. Senior management of the companies will give insights into strategic plans and prospects.